BUZZ-Shanghai Henlius Biotech rises most in 5 months on new drug application
Reuters03-10
BUZZ-<a href="https://laohu8.com/S/SGBCF">Shanghai Henlius Biotech</a> rises most in 5 months on new drug application
** Shares of Shanghai Henlius Biotech Inc 2696.HK rise 8% to HK$71.25, on track for the biggest one-day pct gain since October 8
** Stock touches the highest point since February 23
** China-based biopharmaceutical group said China's National Medical Products Administration had approved an investigational new drug $(IND)$ application for phase 1 clinical trial of HLX316 for injection in patients with advanced/metastatic solid tumours
** Pre-clinical studies have shown that HLX316 exhibits potent antigen-directed desialylation effects on tumour cells in vitro and potential therapeutic benefit for advanced solid tumors - co
** YTD, stock up 22.2%, Hang Seng Biotech Index .HSBIO up 4%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments